

GE Healthcare

P.O. Box 414, W-440

Milwaukee, WI 53201 USA

1. 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR Part 807.87(h).

Identification of Submitter: Larry A. Kroger, Ph.D.

Senior Regulatory Programs Manager

GE Healthcare Tel. (262) 544-3894

Summary prepared: April 25, 2006

Identification of Product:

Digital Fluoroscopic Imaging System

Classification Name:

Fluoroscopic X-ray System GE Medical Systems SCS.

Manufacturer:

283, rue de la Minière 78530 Buc Cedex, France

Distributed by:

GE Medical Systems, LLC, Milwaukee, WI

Marketed Devices:

The GE Healthcare Innova 2121 ^{IQ}, Innova 3131 ^{IQ}, Innova 4100, Innova 4100^{IQ}, Innova 3100, Innova 3100^{IQ}, Innova 2100^{IQ}

devices with *Innova IVUS option* are substantially equivalent to the currently marketed GE Healthcare Innova 2121 $^{\rm IQ}$, Innova 3131 $^{\rm IQ}$, Innova 4100, Innova 4100 $^{\rm IQ}$, Innova 3100, Innova 3100 $^{\rm IQ}$, Innova 2100 $^{\rm IQ}$ devices (K060259, K033244, K052412,

K031637, K050489)

This opinion is based on the information contained in the comparison table and the product data sheets.

Device Description:

The *Innova IVUS* is offered as an option for Innova 2121^{IQ}, Innova 3131^{IQ} (cleared under K060259), Innova 4100 (cleared under K033244), Innova 3100 (cleared under K031637), Innova 2100^{IQ} (cleared under K050489), Innova 4100^{IQ} and Innova 3100^{IQ} (cleared under K052412).

The Innova Digital Fluoroscopic Imaging Systems are designed to perform fluoroscopic x-ray examinations. The detector is comprised of amorphous silicon with a cesium iodine scintillator.

The resulting digital image can be sent through a Fiber Channel link to an acquisition system then to network (in using DICOM) for applications such as post-processing, printing, viewing and archiving. Digital Fluoroscopic Imaging System consists of an a monoplane or biplane positioner, a vascular or cardiac table, an X-RAY system and one or two digital detectors.

The Innova IVUS option provides enhanced connectivity with third party intravascular ultrasound devices.

Materials:

All construction and materials are compliant with UL 187 and IEC 60601-1 for the existing parts of the product and with UL 2601 and IEC 60601-1 for the new parts.

Design:

The design is validated through Failures Modes Effects Analysis (FMEA) process, which allows managing the risks.

Energy Source:

480 VAC 50/60Hz.

Indications for Use: For Innova 2121 IQ, Innova 3131 IQ, Innova 4100, Innova 4100 IQ, Innova 3100, Innova 3100^{IQ}, Innova 2100^{IQ} devices with *Innova* IVUS option:

> The Innova systems are indicated for use in generating fluoroscopic images of human anatomy for vascular angiography, diagnostic and interventional procedures, and optionally, rotational imaging procedures. They are also indicated for generating fluoroscopic images of human anatomy for cardiology, diagnostic, and interventional procedures.

> They are intended to replace fluoroscopic images obtained through image intensifier technology. Those devices are not intended for mammography applications.

Innova IVUS option:

The Innova IVUS software option simplifies the clinical workflow associated with the use of Volcano IVUS products by:

- automatically synchronizing the patient demographic information (patient name, date of birth, DICOM attributes etc.) from Innova system with an IVUS imaging system,
- (2) providing a remote access to commonly used IVUS functions from the Innova table side user interface.
- (3) displaying the IVUS images on the multi-monitor display of the Innova cathlab system.

2/3

Comparison with

The GE Healthcare Innova 2121 ^{IQ}, Innova 3131 ^{IQ}, Innova 4100, Innova 4100^{IQ}, Innova 3100, Innova 3100^{IQ}, Innova 2100^{IQ} devices with Innova IVUS option are substantially equivalent to the currently marketed GE Healthcare Innova 2121 ^{IQ}, Innova 3131 ^{IQ}, Innova 4100, Innova 4100^{IQ}, Innova 3100, Innova 3100^{IQ}, Innova 2100^{IQ} devices (K060259, K033244, K052412, K031637, K050489)

This opinion is based on the information contained in the comparison table and the product data sheets.

Summary of the Studies:

Innova 3131^{IQ}, Innova 2121^{IQ}, Innova 4100, Innova 4100^{IQ}, Innova 3100, Innova 3100^{IQ} and Innova 2100^{IQ} with Innova IVUS option are considered substantially equivalent to the predicates in terms of image quality and diagnostic capabilities. Therefore, previously submitted clinical data are applicable for this submission.

Conclusions:

GE Healthcare considers that Innova IVUS option for Digital Fluoroscopic Imaging Systems Innova 3131^{IQ}, Innova 2121^{IQ}, Innova 4100, Innova 4100^{IQ}, Innova 3100, Innova 3100^{IQ} and Innova 2100^{IQ} to be equivalent with the predicate devices. The potential hazards, related to the introduction of *Innova IVUS* options are controlled by a risk management plan including:

- A hazard identification (Attachment 8)
- A risk evaluation (Attachment 8)
- A Software Development and Validation Process (Attachment 7)



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850

Larry A. Kroger, Ph.D.
Senior Regulatory Programs Manager
GE Medical Systems, LLC
GE Healthcare
P.O. Box 414, W-440
MILWAUKEE WI 53201

JUN - 7 2006

Re: K061163

Trade/Device Name: Digital Fluoroscopic Imaging Systems – Innova 4100, Innova 4100^{IQ}, Innova

3100, Innova 3100^{IQ}, Innova 2100^{IQ}, Innova 3131^{IQ}, Inova 2121^{IQ}, with

Innova IVUS Option.

Regulation Number: 21 CFR 892.1650

Regulation Name: Image-intensified fluoroscopic x-ray system

Regulatory Class: II

Product Code: MQB, IZI, and IYO

Dated: April 25, 2006 Received: April 26, 2006

Dear Dr. Kroger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.



Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150

or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mancy Choadon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

2. Indications for Use

510(k) Number (if known):	X06116	3
Device Name:	Digital Fluoroscopic Imag 4100 ^{IQ} , Innova 3100, Inno 3131 ^{IQ} , Innova 2121 ^{IQ} wi	ing Systems – Innova 4100, Innova va 3100 ^{IQ,} , Innova 2100 ^{IQ,} Innova th Innova IVUS option.
Indications for Use:		
anatomy for vascular angi optionally, rotational imag fluoroscopic images of hu procedures. They are intended to repla technology. Those device	ography, diagnostic and in ing procedures. They are man anatomy for cardiolog ace fluoroscopic images of	ting fluoroscopic images of human nterventional procedures, and also indicated for generating gy, diagnostic, and interventional btained through image intensifier mmography applications.
Innova IVUS option:		
Volcano IVUS products by (1) automatically synchror of birth, DICOM attributes (2) providing a remote accesside user interface.	y: nizing the patient demogra etc.) from Innova system cess to commonly used IV	cal workflow associated with the use of aphic information (patient name, date with an IVUS imaging system, 'US functions from the Innova table display of the Innova cathlab system.
Prescription Use	▼ AMD/OR	Over-The-Counter-Use
(Part 21 CFR 801 Subpart D)	X ANDION	(Part 21 CFR 801 Subpart C)
•	BELOW THIS LINE-CONTIN	IUE ON ANOTHER PAGE IS NEEDED)
	e of CDRH, Office of De	
(Division Sign-Off	A Logeron	

Propagation of the